Meeting Banner
Abstract #0123

Pitching the Cuprizone Mouse Model for Testing (re-) myelination therapies: robustness and reproducibility

Andreas Bruns1, Anna Mechling1, Eva Mracsko1, Thomas Mueggler1, and Basil K√ľnnecke1

1Roche Pharma Research & Early Development, Neuroscience, Ophthalmology and Rare Diseases Discovery & Translational Area, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Basel, Switzerland

We assessed robustness and reproducibility of the cuprizone mouse model of de- and remyelination for its use in testing novel pharmacological treatments of demyelinating disorders such as multiple sclerosis. In several multimodal MRI studies using independent batches of animals, increases in T2, decreases in MTR and FA and biphasic responses in MK upon cuprizone feeding, as well as partial recoveries after cuprizone withdrawal, showed huge effect sizes and high cross-study consistency, especially in the corpus callosum. Our results substantiate the suitability of the cuprizone mouse model for longitudinal monitoring of the pathology using multimodal MRI.

This abstract and the presentation materials are available to members only; a login is required.

Join Here